Infectious markers
Reliable in vitro diagnostic devices (IVD) for infectious markers such as hepatitis B and C as well as HIV which are used for screening of blood donations are the prerequisite for the manufacturing of safe blood and blood products. IVDs have reached a high quality and blood products have become much safer since the introduction of modern technologies in the recent years. However, more effort is still needed for the transfer of those technologies around the world to make safe blood common worldwide.
Regulatory authorities do need every possible support to get the technical know-how to build up the regulatory instruments needed for market authorization and production control of IVDs. Besides effective standards for Good Manufacturing Practices (GMP), quality assurance as well as vigilance systems as general tools, regulatory bodies need to build up specific quality criteria for
- Licensing
- Batch release control
- Re-evaluation
of in vitro diagnostic devices that depend on the respective marker.
Those criteria should help to guarantee products of high quality as well as consistent production of IVD batches. High quality of IVDs first of all means to reach the highest possible sensitivity, i.e. recognition of positive samples which needs to be linked to the ability of the assays to make a clear distinction between positive and negative samples.
Many of the IVD assays base their distinction of positive and negative results upon mathematical calculations by using calibrators. Positive and negative controls are provided together with the assays to verify calibration and to control the homogeneity of performance. Those calibrators and controls are developed by manufacturers themselves or are referred to international reference materials.
WHO provides International Reference Materials which contribute to the global harmonization of blood donation and patient testing, to get reliable and constant results of IVDs and to allow the communication of results in a common language worldwide.
These preparations have been developed both for the standardization of nucleic acid amplification technologies and immunoassays.
Reference preparations are established for:
Hepatitis B markers:
-
Principles in Evaluation of HBsAg Test Kits: Appropriate Use of 2nd WHO International Standard (IS) and Reference Panel for HBsAg (WHO, Geneva, Nov 2004)
pdf, 24kb -
Hepatitis B surface antigen, subtype adw2, genotype A, Lyophilized. 2nd Int. Standard; 33 IU / vial. (WHO/BS/03.1987)
pdf, 1.05Mb -
Instructions for use
pdf, 51kb -
Hepatitis B surface antigen, subtype adw2, genotype A, Lyophilized. Reference Panel (IU / vial: 8.25; 2.06; 0.52; 0.13) (WHO/BS/03.1987)
pdf, 1.05Mb -
Instructions for use
pdf, 57kb -
Hepatitis B virus DNA, Lyophilized. 500,000 IU / vial. (WHO/BS/99.1917)
pdf, 2.61Mb -
Instructions for use
pdf, 47kb -
Anti-hepatitis B immunoglobulin, human. Lyophilized. 50 IU / ampoule. (WHO/BS/77.1164)
pdf, 1.83Mb -
Instructions for use
pdf, 140kb
Hepatitis C markers:
-
Hepatitis C virus RNA, Lyophilized. 50,000 IU / vial. (WHO/BS/97.1861)
pdf, 11.08Mb -
Replacement study (WHO/BS/03.1958)
pdf, 47kb -
Instructions for use
pdf, 49kb
HIV markers:
-
HIV-1 p24 antigen, Lyophilized. 1,000 IU / ampoule. (WHO/BS/92.1699)
pdf, 2.06Mb -
Instructions for use
pdf, 52kb -
HIV-1 RNA, Lyophilized. 100,000 IU / vial. (WHO/BS/99.1910)
pdf, 9.46Mb -
Instructions for use
pdf, 64kb -
HIV-1 RNA genotypes (set of 10 genotypes). Liquid. 1.1 ml/vial. WHO/BS/03.1961
pdf, 78kb -
Instructions for use
pdf, 61kb
HAV markers:
-
Hepatitis A RNA, Lyophilized. 50000 IU / vial. (WHO/BS/03.1959)
pdf, 334kb -
Instructions for use
pdf, 49kb
Parvovirus B19 markers:
-
Parvovirus B19 DNA human, Lyophilized. 500 000 IU / ampoule. (WHO/BS/00.1928)
pdf, 3.68Mb -
Instructions for use
pdf, 46kb
-------------------------------------------------------------------------
Other WHO International Reference Materials
The characteristics of all reference preparations as well as the information regarding establishment can be found in the WHO Reference Material section.
Related documents
-
WHO Consultation on Global Measurement Standards and their use in the in vitro Biological Diagnostic Field. Geneva, Switzerland (Jun 2004)
pdf, 69kb -
WHO Working Group on International Reference Preparations for Testing Diagnostic Kits used in the Detection of HBsAg and anti-HCV Antibodies (Oct 2003)
pdf, 60kb -
WHO Consultation on International Standards for in vitro Clinical Diagnostic Procedures based on Nucleic Acid Amplification Techniques (NAT). Geneva, Switzerland (Apr 2002)
pdf, 72kb -
WHO Working Group on Reference Preparations for testing Diagnostic Kits used for detection of HBsAg, Anti-HCV and Anti-HIV antibodies in blood screening. Geneva, Switzerland (Jan 2000)
pdf, 60kb